During her presentation, Mrs. Sánchez-Matamoros exposed the main results of a study whose objective was to evaluate the efficacy of vaccination with ERAVAC® (inactivated vaccine against rabbit haemorrhagic disease type 2) in rabbits for up to 12 months post-vaccination.
These results improve our vaccination knowledge for designing both annual revaccination and emergency vaccination programmes against RHD-2.
With this initiative, HIPRA demonstrates its support for the rabbit industry and affirms its commitment to the prevention of RHD-2.
